AlphaCentric Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

AlphaCentric Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,478	Closed	-$287K	–	253
2024 Q3	$287K	Buy	+11,478	New	+$280K	0.21%	111
2023 Q4	–	Sell	-110,000	Closed	-$1.91M	–	266
2023 Q3	$1.91M	Hold	110,000	–	–	1.08%	30
2023 Q2	$1.55M	Buy	110,000 +27,500	+33%	+$368K	0.86%	43
2023 Q1	$888K	Buy	82,500 +37,500	+83%	+$494K	0.61%	59
2022 Q4	$674K	Buy	45,000 +2,000	+5%	+$29.1K	0.67%	55
2022 Q3	$552K	Buy	+43,000	New	+$490K	0.57%	53
2021 Q3	–	Sell	-32,500	Closed	-$453K	–	211
2021 Q2	$453K	Buy	32,500 +13,500	+71%	+$205K	0.12%	68
2021 Q1	$352K	Buy	19,000 +3,500	+23%	+$71.6K	0.12%	66
2020 Q4	$274K	Buy	15,500 +11,500	+288%	+$202K	0.11%	46
2020 Q3	$61K	Buy	+4,000	New	+$75.1K	0.03%	93

Other funds holding KNSA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

AlphaCentric Advisors's KNSA Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2024, closing a stake of 11,478 shares — an estimated $287K sold.

AlphaCentric Advisors first reported a position in KNSA in Q3 2020 and held it in 10 quarters. The position peaked at $1.91M in Q3 2023. 160 funds tracked by Wall St. Rank hold KNSA as of Q4 2024.

AlphaCentric Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
AlphaCentric Advisors sold 11,478 Kiniksa Pharmaceuticals shares in Q4 2024, an estimated $287K.
AlphaCentric Advisors first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 10 quarters.
AlphaCentric Advisors's Kiniksa Pharmaceuticals position peaked at $1.91M in Q3 2023.
160 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.